**CLAIMS**

1. Use of an Anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment for the manufacture of a medicament for intervention and therapy of congestion in a patient in need thereof, wherein said anti-ADM antibody or anti-ADM fragment binds to the N-terminal part (aa 1-21) of adrenomedullin:

YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 22),

and wherein said patient is resistant against diuretics or is a non-responder to diuretics therapy.

2. Use of an Anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment for the manufacture of a medicament for intervention and therapy of congestion in a patient according to claim 1, wherein said patient has a disease or condition selected from the group comprising congestive high blood pressure, swelling or water retention (edema), heart failure in particular acute heart failure, kidney or liver disease.

3. Use of an Anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment for the manufacture of a medicament for intervention and therapy of congestion in a patient according to claim 1 or 2, wherein said patient has a disease or condition selected from the group comprising congestive high blood pressure, swelling or water retention (edema), and heart failure, in particular acute heart failure.

4. Use of an Anti-Adrenomedullin (ADM) antibody or an anti-ADM antibody fragment for the manufacture of a medicament for intervention and therapy of congestion in a patient according to any one of claims 1 to 3, wherein said antibody or antibody fragment is monospecific.

5. Use of an Anti-Adrenomedullin (ADM) antibody or an anti-ADM antibody fragment for the manufacture of a medicament for intervention and therapy of congestion in a patient according to any one of claims 1 to 4, wherein said antibody or fragment exhibits a binding affinity to ADM of at least $10^{-7}$ M.

6. Use of an Anti-ADM antibody or an anti-ADM antibody fragment for the manufacture of a medicament for intervention and therapy of congestion in a patient according to any one of claims 1 to 5, wherein said antibody or fragment recognizes and binds to the N-terminal end (aa 1) of adrenomedullin.

7. Use of an Anti-Adrenomedullin (ADM) antibody or an anti-ADM antibody fragment for the manufacture of a medicament for intervention and therapy of congestion in a patient according to any one of claims 1 to 6, wherein said antibody or antibody fragment does not bind to the C-terminal portion of ADM, having the sequence aa 43-52 of ADM

PRSKISPQGY-$NH_2$
(SEQ ID NO: 24).

8. Use of an Anti-ADM antibody or an anti-ADM antibody fragment for the manufacture of a medicament for intervention and therapy of congestion in a patient according to any one of claims 1 to 7, wherein said antibody or fragment or scaffold blocks the bioactivity of ADM not more than 80 %, preferably not more than 50%.

9. Use of an Anti-ADM antibody or an anti-ADM antibody fragment for the manufacture of a medicament for intervention and therapy of congestion in a patient according to any one of claims 1 to 8, wherein said patient is an ICU patient.

10. Use of an Anti-ADM antibody or an anti-ADM antibody fragment for the manufacture of a medicament for intervention and therapy of congestion in a patient according to any one of claims 1 to 9, wherein said antibody or fragment is a human monoclonal antibody or fragment that binds to ADM or an antibody fragment thereof wherein the heavy chain comprises the sequences:

SEQ ID NO: 1
GYTFSRYW;

SEQ ID NO: 2
ILPGSGST; and

SEQ ID NO: 3
TEGYEYDGFDY

and wherein the light chain comprises the sequences:

SEQ ID NO: 4
QSIVYSNGNTY;

SEQUENCE: RVS; and

SEQ ID NO: 5
FQGSHIPYT.

11. Use of a human monoclonal antibody or fragment that binds to ADM or an antibody fragment thereof for the manufacture of a medicament for intervention and therapy of congestion in a patient according to claim 10, wherein said antibody or fragment comprises a sequence selected from the group comprising:

SEQ ID NO: 6 (AM-VH-C)
QVQLQQSGAELMKPGASVKISCKATGYTFSRYWIEWVKQRPGHGLEWIGEILP
GSGSTNYNEKFKGKATITADTSSNTAYMQLSSLTSEDSAVYYCTEGYEYDGFD
YWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR
VEPKHHHHHH;

SEQ ID NO: 7 (AM-VH1)
QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWISWVRQAPGQGLEWMGRIL
PGSGSTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCTEGYEYDGFD
YWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR
VEPKHHHHHH;

SEQ ID NO: 8 (AM-VH2-E40)

QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWIEWVRQAPGQGLEWMGRIL
PGSGSTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCTEGYEYDGFD
YWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR
VEPKHHHHHH;

SEQ ID NO: 9 (AM-VH3-T26-E55)
QVQLVQSGAEVKKPGSSVKVSCKATGYTFSRYWISWVRQAPGQGLEWMGEIL
PGSGSTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCTEGYEYDGFD
YWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR
VEPKHHHHHH;

SEQ ID NO: 10 (AM-VH4-T26-E40-E55)
QVQLVQSGAEVKKPGSSVKVSCKATGYTFSRYWIEWVRQAPGQGLEWMGEIL
PGSGSTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCTEGYEYDGFD
YWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR
VEPKHHHHHH;

SEQ ID NO: 11 (AM-VL-C)
DVLLSQTPLSLPVSLGDQATISCRSSQSIVYSNGNTYLEWYLQKPGQSPKLLIYR
VSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHIPYTFGGGTKLE
IKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS
QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE
C;

SEQ ID NO: 12 (AM-VL1)
DVVMTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLNWFQQRPGQSPRRLIYR
VSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYTFGQGTKL
EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG
EC; and

SEQ ID NO: 13 (AM-VL2-E40)
DVVMTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLEWFQQRPGQSPRRLIYR
VSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYTFGQGTKL
EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG
EC.

12. Use of an Anti-ADM antibody or anti-ADM antibody fragment for the manufacture of a medicament for intervention and therapy of congestion in a patient according to any one of claims 1-11, wherein a sample of bodily fluid taken from said patient exhibits an elevated level of proADM and/or fragments thereof having at least 5 amino acids above a certain threshold.

13. Use of a pharmaceutical formulation comprising an antibody or fragment according to any one of claims 1 to 12 for the manufacture of a medicament for intervention and therapy of congestion in a patient, wherein said patient has a disease or condition selected from the group comprising congestive high blood pressure, swelling, heart failure in particular acute heart failure, kidney or liver disease and wherein said patient is resistant to diuretics or is a non-responder to diuretics therapy.

14. Use of a pharmaceutical formulation for the manufacture of a medicament for intervention and therapy of congestion in a patient according to claim 13, wherein said pharmaceutical formulation is a solution, preferably a ready-to-use solution.

15. Use of a pharmaceutical formulation for the manufacture of a medicament for intervention and therapy of congestion in a patient according to claim 14, wherein said pharmaceutical formulation is in a freeze-dried state.

16. Use of a pharmaceutical formulation for the manufacture of a medicament for intervention and therapy of congestion in a patient according to claim 14 or 15, wherein said pharmaceutical formulation is to be administered intra-muscular.

17. Use of a pharmaceutical formulation for the manufacture of a medicament for intervention and therapy of congestion in a patient according to claim 14 or 15, wherein said pharmaceutical formulation is to be administered intra-vascular.

18. Use of a pharmaceutical formulation for the manufacture of a medicament for intervention and therapy of congestion in a patient according to claim 17, wherein said pharmaceutical formulation is to be administered via infusion.

19. Use of a pharmaceutical formulation for the manufacture of a medicament for intervention and therapy of congestion in a patient according to any one of claims 14 to 18, wherein said pharmaceutical formulation is to be administered systemically.